New "Decision to grant" communications in Europe and Japan MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that the European Patent Office has issued a "Decision to grant" communication for its European patent application EP20712563.4 relating to vafidemstat. The patent, titled "Methods of treating Attention Deficit Hyperactivity Disorder usin ...